Detalhe da pesquisa
1.
HBA1C CONTROL AND COST-EFFECTIVENESS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INITIATED ON CANAGLIFLOZIN OR A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST IN A REAL-WORLD SETTING.
Endocr Pract
; 24(3): 273-287, 2018 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-29547044
2.
Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors.
BMC Endocr Disord
; 17(1): 32, 2017 Jun 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28595617
3.
Assessment of racial and ethnic inequities in copay card utilization and enrollment in copay adjustment programs.
J Manag Care Spec Pharm
; 29(9): 1084-1092, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37548953
4.
Treatment patterns, glycemic control and bodyweight with canagliflozin 300 mg versus GLP1RAs in Type II diabetes patients.
J Comp Eff Res
; 8(11): 889-905, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31167554
5.
An investigation into the durability of glycemic control in patients with type II diabetes initiated on canagliflozin or sitagliptin: A real-world analysis of electronic medical records.
J Diabetes Complications
; 33(2): 140-147, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30554838
6.
The cost-effectiveness of atypicals in the UK.
Value Health
; 11(7): 1007-21, 2008 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-18489517
7.
Quality goal attainment and maintenance in patients with type II diabetes mellitus initiated on canagliflozin or a glucagon-like peptide-1 receptor agonist in an actual practice setting.
Curr Med Res Opin
; 34(6): 1125-1133, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29557199
8.
Retrospective Study on the Impact of Adherence in Achieving Glycemic Goals in Type 2 Diabetes Mellitus Patients Receiving Canagliflozin.
Adv Ther
; 34(4): 937-953, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28251556
9.
Shared decision-making for biologic treatment of autoimmune disease: influence on adherence, persistence, satisfaction, and health care costs.
Patient Prefer Adherence
; 11: 947-958, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28572722
10.
Effectiveness of step therapy policies for specialty pharmaceuticals in immune disorders.
J Med Econ
; 18(8): 646-53, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25830699